Futures were muted after a largely rangebound session on Wall Street, although technology shares marked some gains. Chipmaking majors such as Nvidia (NASDAQ: NVDA) and AMD gained on hopes that ...

Oil prices steadied Monday, retaining most of last week’s gains as traders watched for news from the U.S.-China trade talks ...

Investing.com -- Block Inc’s Square has unveiled its new artificial intelligence tool, Square AI, which is currently ...

The company’s stock movement reflects market reaction to the potential increase in debt and the implications of the convertible notes on shareholder value. The financial maneuvers, including the ...

Investing.com -- President Donald Trump took a more neutral tone toward Tesla (NASDAQ:TSLA) CEO Elon Musk in a press conference on Monday after the close relationship between the two blew up in public ...

Cracker Barrel aims to use the net proceeds from this offering for general corporate purposes, which may include redeeming or repaying existing indebtedness, such as the 0.625% convertible senior ...

The citrus grower posted a loss of -$0.17 per share for the quarter ended April 30, missing the analyst estimate of $0.04 profit. Revenue came in at $35.1 million, well below the consensus forecast of ...

Investing.com -- U.S. President Donald Trump stated on Monday that discussions between the U.S. and Iran regarding a nuclear deal will carry on this coming Thursday. Trump acknowledged that Tehran was ...

Investing.com -- Fitch Ratings has upgraded the Rating Outlook for FLEX Ltd. from Stable to Positive, while affirming its Long-Term Issuer Default Rating (IDR), senior unsecured notes ratings, and ...

“Payment resumption may pressure other delinquencies, as student borrowers are more likely to miss payments on other debt.

Investing.com -- The global video gaming industry is entering a new era of pricing power, platform shifts, and AI-driven innovation, with Bernstein forecasting a return to growth in 2025 after a ...

Avidity Biosciences, based in San Diego, reported that it has confirmed with the FDA that the accelerated approval pathway is open for its investigational therapy, del-brax. This therapy is designed ...